09 March 2023
Coulter Partners places Vice President of Intellectual Property at Amphista Therapeutics
Coulter Partners recently partnered with Amphista Therapeutics to further strengthen their team in Cambridge with the appointment of Dr Victoria Lovatt as Vice President of Intellectual Property.
Amphista Therapeutics is a leader in next generation targeted protein degradation (TPD) approaches and is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in TPD that address the challenges faced by earlier stage TPD research, and to realize the full therapeutic potential of this transformational approach.
Victoria is an IP strategist who brings a wealth of expertise from her experience working across the globe in the biotech and pharmaceuticals sectors.
Nicola Thompson, CEO of Amphista, comments: “I am delighted to welcome Victoria as our Vice President of Intellectual Property. Her specialist knowledge will support us as we continue our work to unlock the full potential of next generation TPD technology in order to bring transformative medicines to patients.”
She adds: “We would like to thank the team at Coulter Partners for their support in securing Victoria’s appointment; we were highly impressed with their professional expertise and extensive market knowledge.”
Victoria joins Amphista from Mundipharma where she was Director of IP Strategy. Prior to that, she held IP roles across the biotechnology and pharmaceutical industries. Victoria is a chartered UK patent attorney, a European patent attorney and a Singapore patent attorney. She holds a BSc (Hons) in Chemistry/Biochemistry from Nottingham University, UK and a PhD in Neuroimmunology from the University of Cambridge, UK.
Commenting on her appointment, Victoria remarks: “I am delighted to join Amphista’s world class team. Amphista is founded on transformational science and I’m looking forward to building on strong IP foundations to develop a broad strategic IP portfolio as we execute our mission of building the leading TPD company.”
About Amphista Therapeutics
Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Advent Life Sciences, Forbion, Gilde Healthcare, Novartis Venture Fund, Eli Lilly & Company, and Dementia Discovery Fund.
For more information, please visit: https://amphista.com
Top hires for VC & PE portfolio companies Q1-2022
28 April 2022
Coulter Partners finds Chief Medical Officer for Memo Therapeutics AG
13 July 2021
Top global hires for large-cap, mid-cap and public companies
07 October 2020
Coulter Partners secures Chief Financial Officer for Stilla Technologies
28 January 2020